Special Considerations in the Management of HIV-Infected Patients From Minority Communities

  • Authors: Bisola Ojikutu, MD, MPH; Valerie E. Stone, MD, MPH (More Info)
  • Section Editor: Judith S. Currier, MD, MSc
  • Editors in Chief: Daniel R. Kuritzkes, MD; Joseph J. Eron, Jr., MD
  • Last Reviewed: 7/9/18 (What's New)

Summary

  • WHO guidelines recommend giving oral tenofovir DF–containing PrEP with other preventive strategies to patients with substantial risk of HIV infection including subgroups of MSM and transgender women[WHO 2016]
  • Several clinical trials enrolling MSM and transgender women have demonstrated high efficacy of emtricitabine/tenofovir DF given as PrEP[McCormack 2016; Molina 2015]
  • Adherence is generally high in patients engaging in high risk behaviors[Liu 2016; Hosek 2017]

    Action required